Brief: Orexo Announces Positive Pharmacokinetic In-Vivo Data For Powder-Based Intranasal Semaglutide Formulation

Orexo AB

05/09/2025 08:07

Sept 5 (Reuters) - Orexo AB ORX.ST:

ANNOUNCED POSITIVE PHARMACOKINETIC IN-VIVO DATA FOR A POWDER-BASED INTRANASAL SEMAGLUTIDE FORMULATION DEVELOPED WITH AMORPHOX TECHNOLOGY

DATA GENERATED FURTHER SUPPORTS ABILITY OF AMORPHOX TECHNOLOGY TO FORMULATE LARGE MOLECULES INTO POWDERS THAT COULD BE DELIVERED INTRANASALLY

Source text: ID:nMFN59y7X2

Further company coverage: ORX.ST

 (Gdansk Newsroom)

 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))